Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-11-20
2007-11-20
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S133100, C424S135100, C530S388730, C530S387300
Reexamination Certificate
active
10386204
ABSTRACT:
The present invention provides novel immunotoxins and methods of treating neoplastic diseases. These immunotoxins are comprised of a conjugation of an antigen binding region exhibiting binding specificity for the CD33 protein and a cell growth modulator. The immunotoxins of the present invention specifically and selectively kill tumor cells that are characterized by the expression of CD33 antigen. Thus, the novel immunotoxins would be useful in treating human leukemias, both acute and chronic, and other myelodysplastic syndromes.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5455030 (1995-10-01), Ladner et al.
patent: 5514554 (1996-05-01), Bacus
patent: 5571894 (1996-11-01), Wels et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5631348 (1997-05-01), Rosenblum et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5730982 (1998-03-01), Scheinberg
patent: 5744580 (1998-04-01), Better et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5837491 (1998-11-01), Better et al.
patent: 5977322 (1999-11-01), Marks et al.
patent: 6054561 (2000-04-01), Ring
patent: 6146631 (2000-11-01), Better et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6204023 (2001-03-01), Robinson et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6387371 (2002-05-01), Hudziak et al.
patent: 6399063 (2002-06-01), Hudziak et al.
patent: 6512097 (2003-01-01), Marks et al.
patent: 6649742 (2003-11-01), Better et al.
patent: 0350230 (1990-01-01), None
patent: WO 91/09058 (1991-06-01), None
patent: WO 93/20848 (1993-10-01), None
Tanimoto et al Leukemia vol. 3 p. 339 (1989).
Scheinberg et al Leukemia vol. 3 p. 440 (1989).
Thrope et al Immunological Reviews vol. 62 p. 119 (1982).
Andrews et al., “Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies,”Blood, 62:124-132, 1983.
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a signal lysine residue,”J. Cell. Biol., 111:2129-2138, 1990.
Chaudhary et al., “A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheris toxin,”Proc. Natl. Acad. Sci. USA, 87:9491-9494, 1990.
Co et al., “Chimeric and humanized antibodies with specificity for the CD33 antigen,”J. Immunol., 148:1149-1154, 1992.
Cunningham et al., “Antibody engineering-how to be human,”Trends Biotechnol., 10:112-113, 1992.
Engert et at ., “Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins,”Leuk. Res., 15(11):1079-1086, 1991.
Gillies et al., “Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities,”Hum. Antibodies Hybridomas., 1:47-57, 1990.
Houghton and Scheinberg, “Monoclonal antibodies: potential applications to the treatment of cancer,”Semin. Oncol., 13(2):165-179, 1986.
La Russa et al., “Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ Human marrow cells to establish in vitro hematoplesis in long-term marrow cultures,”Exp. Hematol., 20:442-448, 1992.
Lambert et al., “An immunotoxinprepared with blocked ricin: a natural plant toxin adapted for therapeutic use,”Cancer Res., 51:6236-6242, 1991.
Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,”Mol. Cell. Biol., 8:1247-1252, 1988.
Maier et al., “Requirements for the internalization of a murine monoclonal antibody directed against the HER-2
eu gene product c-erbB-2.”Cancer Res.51:5361-5369, 1991.
Milenic et al., “Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49,”Cancer Res., 51:6363-6371, 1991.
Morrison et al., “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,”Proc. Natl. Acad. Sci. USA, 81:6851-6855, 1984.
Ozawa et al., “Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor,”Int. J. Cancer, 43(1):152-157, 1989.
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. USA, 86:10029-10033, 1989.
Reichmann et al., “Reshaping human antibodies for therapy,”Nature, 332:323-327, 1988.
Roy et al., “Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells,”Blood, 77(11):2404-2412.
Scheinberg et al., “Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia,”Leukemia, 3:440-445, 1989.
Scheinberg et al., “A phase I Trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide,”J. Clin. Oncol., 9:478-490, 1991.
Scheinberg et al., “Humanized and mouse anti-CD33-gelonin immunitoxins for myeloid luekemias,”Proceedings of the American Association for Cancer Research,33:346, Mar. 1992.
Scott et al., “An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors,”J. Natl. Cancer Inst., 79:1163-1172, 1987.
Sivam et al., “Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates,”Cancer Res., 47:3169-3173, 1987.
Stripe and Barbieri, “Ribosome-inactivating proteins up to date,”FEBS Lett., 195:1-8, 1986.
Stripe et al., “Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and prepared of cytotoxic complexes with concanavalin A,”J. Biol. Chem., 255:6947-6953, 1980.
Tanimoto et al., “Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195,”Leukemia,3:339-348, 1989.
Tao and Morrison, “Studies aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region,”J. Immunol., 143:2595-2601, 1989.
Tecce et al., “Production and characterazation of immunotoxins to distinct epitopes of the extracellular domain of the HER-2 gp185,”Anticancer Res., 10:1454, abstract 329, 1990.
Thorpe and Ross, “The preperations and cytotoxic properties of antibody-toxin conjugates,”Immunol. Rev., 62:119-158, 1982.
Thorpe et al., “New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo,”Cancer Res., 47:5924-5931, 1987.
Waldmann, “Monoclonal antibodies in diagnosis and therapy,”Science, 252:1657-1662, 1991.
Fulbright & Jaworski L.L.P.
Huff Sheela J.
Research Development Foundation
LandOfFree
Immunotoxins directed against CD33 related surface antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotoxins directed against CD33 related surface antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotoxins directed against CD33 related surface antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861110